Filing Flows › Sonoma Pharmaceuticals (SNOA) › Q2 FY26
Sonoma Pharmaceuticals (SNOA) Q2 FY26 earnings results (second quarter fiscal 2026)
10-Q filed Nov 4, 2025
Sonoma Pharmaceuticals (SNOA) reported revenue of $5.6M for the second quarter fiscal 2026 (Q2 FY26), +57% from a year earlier and +40% from the quarter before. Operating margin was -6.0%, net loss $534K (9.5% of revenue).
Sonoma Pharmaceuticals, Q2 FY26: revenue $5.6M (+57% year over year), operating margin -6.0%, net loss $534K, operating cash flow −$635K. The chart follows the revenue to costs, profit and cash.
| Q2 FY26 | Amount | Q/Q | Y/Y |
|---|---|---|---|
| Revenue | $5.6M | +40% | +57% |
| Operating profit | −$337K | — | — |
| Net earnings | −$534K | — | — |
| Operating cash flow | −$635K | — | — |
What changed
Revenue was $5.6M in Q2 FY26, up 57% year over year and up 40% from the previous quarter.
Gross margin was 37.8%, down 0.2 points from a year earlier. Operating costs exceeded revenue by $337K, an operating margin of -6.0%. Operating expenses grew 11% against revenue growth of 57%. The fastest-growing cost line was Research & development (+14%). The quarter ended with a net loss of $534K, narrower than the previous quarter's $1.2M loss. Net interest and other expense of $394K was the main reason.
Operating cash flow was −$635K. Non-cash charges added back $36K of depreciation and amortization and $39K of share-based compensation. Working capital and other items used $176K. Capital expenditures of $10K exceeded it, leaving free cash flow of −$645K.
Questions
What was Sonoma Pharmaceuticals' revenue in the second quarter fiscal 2026?
Sonoma Pharmaceuticals (SNOA) reported revenue of $5.6M for the second quarter fiscal 2026 (Q2 FY26), +57% from a year earlier and +40% from the quarter before.
Was Sonoma Pharmaceuticals profitable in the second quarter fiscal 2026?
Operating loss was $337K (-6.0% of revenue) and net loss $534K.